#Bioretec #Finland #Tampere #RemeOs #biodegradable implants

Bioretec Ltd Expands Share Capital with New Registrations

Bioretec Ltd, a Finnish company specializing in medical devices, has successfully registered a total of 60,000 new shares following its option rights program (2018-1A). The shares, subscribed on May 20, 2025, have been recorded with the Finnish Patent and Registration Office, marking a key milestone for the company.

The total subscription price reached EUR 90,000, which will be included in Bioretec's reserve of invested unrestricted equity. Notably, the company’s overall share capital will remain unchanged despite this increase in share quantity. Following this registration, Bioretec now has a total of 24,626,474 shares.

These new shares will be issued using the book-entry system starting on May 21, 2025, and shareholders can expect their trading to begin on Nasdaq First North Growth Market Finland by May 22, 2025. This development is significant not only for Bioretec but also for its investors, as the newly issued shares will provide rights equivalent to existing shares from the day of registration.

Innovation in Orthopedic Technology

Bioretec is renowned for its dedication to pioneering biodegradable orthopedic implants. The company leverages unique expertise in creating products that enhance bone growth and promote faster healing following surgical interventions. The patented RemeOs™ product line is particularly noteworthy. It features a new generation of strong biodegradable materials composed of magnesium alloy and hybrid composites. RemeOs™ implants are absorbed and replaced by bone, negating the need for subsequent removal surgeries and contributing to improved surgical outcomes.

With a growing presence, Bioretec aims to tap into the lucrative global orthopedic trauma and spine market, estimated at over USD 9 billion. Transitioning away from traditional titanium implants, Bioretec’s innovative offerings hold the potential to redefine standards in surgical treatment for bone fractures and significantly enhance patient care.

The organizational structure of Bioretec reflects its commitment to excellence. Sarah van Hellenberg Hubar-Fisher is serving as the Interim CEO, indicating strong leadership continuity during this pivotal growth period. The company is also supported by its certified adviser, Nordic Certified Adviser AB, ensuring compliance and fostering development.

Market Authorizations

Bioretec has secured essential market authorizations for its innovative products. In March 2023, Bioretec received approval for the RemeOs™ product line in the U.S., followed by the CE mark certification in Europe in January 2025. These approvals underscore the company’s dedication to enhancing the quality of life through better medical technology, emphasizing the slogan: Better healing - Better life.

For investors and stakeholders, Bioretec presents a compelling opportunity driven by cutting-edge research and a commitment to advancing healthcare solutions. As Bioretec marks this new chapter with the issuance of additional shares, the outlook remains positive for the company’s future trajectory in the rapidly evolving medical device landscape.

For more information, you can visit Bioretec's official website.